MYCN and medulloblastoma: In our experience, we included in the Milano strategy only patients with metastatic disease until 2007, thereafter we included patients whose medulloblastoma had LC/A morphologic subtypes, TP53 mutation, and/or MYC and MYCN amplifications.4,23